Computer Algorithms Automatically Detect Malaria in Stained Blood Smears
|
By LabMedica International staff writers Posted on 10 Aug 2015 |
|
Image: The Parasight platform: computer vision technology scans stained blood samples under a fluorescent microscope and detects the presence of malaria parasites in blood cells (Photo courtesy of Sight Diagnostics).
An Israeli startup company has developed a computerized platform that detects anomalies in stained blood cell samples—such as those infected by the malaria parasite—faster and more accurately than the human eye.
Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.
The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.
The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.
Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.
“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”
Related Links:
Sight Diagnostics
Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.
The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.
The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.
Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.
“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”
Related Links:
Sight Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
HPV Test
Allplex HPV28 Detection
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Microbiology News
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Pathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
